학술논문
154P Five-year follow-up of the phase III study comparing SB3 (trastuzumab biosimilar) and reference trastuzumab in patients with HER2 positive early or locally advanced breast cancer
Document Type
Abstract
Author
Source
In Annals of Oncology September 2021 32 Supplement 5:S428-S428
Subject
Language
ISSN
0923-7534